Biosimilar antibody therapeutic - Abzena

Drug Profile

Biosimilar antibody therapeutic - Abzena

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abzena
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Multiple sclerosis

Most Recent Events

  • 19 Oct 2017 Abzena and UGA Biopharma enter into a partnership to develop a cell line expressing the biosimilar antibody therapeutic for Multiple Sclerosis
  • 19 Oct 2017 Early research in Multiple sclerosis in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top